Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
CureTech
August 22, 2016
Pfizer pays up
January 27, 2016
Medivation is not the first to be overturned on further review
August 24, 2015
Biomarin goes for pragmatism as the markets dip
July 28, 2015
Oncology latecomers put early assets in partnering frame
December 15, 2014
SABCS – Combo and diagnostic drive Xtandi’s breast cancer opportunity
November 13, 2014
Market pre-empts Medivation’s next catalyst
October 24, 2014
Biotech’s immuno-oncology laggards place their bets
June 07, 2012
Therapy focus – PD-1s show worth at Asco
September 14, 2011
Teva optimising CureTech investment
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
November 29, 2021
Biopharma Quarterly Round Up (Q3 2021)
November 16, 2021
Covid Round Up (2021)
Editor's Picks
November 22, 2021
The bubble bursts for biotech stocks
November 08, 2021
Ash 2021 preview – as competition grows Autolus monetises
November 23, 2021
Ash 2021 late-breakers enable neat comparisons
November 04, 2021
What Novartis could buy with its windfall
November 16, 2021
Fate buries bad data and moves on
